Company's multiplex rapid tests for
HIV, syphilis, hepatitis B and C to be used in
mobile clinics
HALIFAX,
Jan. 28,
2015 /CNW/ - MedMira Inc. (MedMira)
(TSXV: MIR) has received payment for an initial $100,000 order of its Multiplo rapid tests which
will be used in a collaborative mobile health initiative in
Uzbekistan.
Donated by the Government of the Russian
Federation and aligned with UNAIDS and World Health
Organization (WHO) global health priorities, these innovative
mobile clinics are mini hospitals on wheels that travel to the most
remote areas of a country providing cutting edge medical services,
which would be otherwise unavailable. The
unique, portable, and easy-to-use Multiplo rapid tests will enable
Uzbekistan's Republican AIDS
Center, the organization operating the mobile clinics, to provide
highly accurate, on-the-spot screening and prevention initiatives
for HIV, syphilis (TP), hepatitis B (HBc) and C
(HCV).
"Working with UNAIDS and other collaborators on this
important program in Uzbekistan is
garnering international recognition for our Multiplo products. We
fully support the work of UNAIDS and related organizations,
including the WHO, UNICEF and World Bank, and look forward to being
a part of their screening and prevention programs in Central Asian
countries, such as Uzbekistan,"
said Hermes Chan, CEO, MedMira Inc.
"MedMira's rapid tests, built on our innovative RVF technology
platform, have a role to play in screening programs, regardless of
whether the testing is performed in a state-of-the-art hospital lab
or the back of a mobile clinic vehicle in the field. No other
technology can match the speed, ease of use, and the versatility of
Multiplo tests."
UNAIDS unites the efforts of 11 UN organizations – UNHCR,
UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO, and
the World Bank – and works in conjunction with the Republican AIDS
Center, part of the Ministry of Health of the Republic of
Uzbekistan, to facilitate
innovative screening programs that localize global health
strategies and initiatives. MedMira's Multiplo
rapid tests, which deliver multiple, instant results, will enable
to the Center to simultaneously double or triple its testing and
prevention efforts in the mobile
clinics.
Chan continued "Equipped with Multiplo tests, the mobile
clinics in Uzbekistan can increase
screening efforts to prevent the spread of not just a single
disease but now HIV, syphilis, hepatitis B and C at the same
time. As healthcare providers, aid
organizations, and public health agencies around the world
implement our unique products, they immediately realize the value
and benefits that are brought to their programs.
These benefits include fewer patients lost to follow-up and being
able to provide immediate counselling and treatment because of the
speed of the tests; as well as maximizing resource utilization and
improving the bottom line by delivering multiple results on a
single test."
Multiplo TP/HIV and Multiplo HBc/HIV/HCV tests are already
being used in testing programs in several Latin America countries and in programs in
India. Additionally, the Multiplo
TP/HIV test is in the final technical evaluation phase of the WHO
Prequalification of Diagnostics program and MedMira is conducting
multi-center clinical trials to support United States FDA approval
for the Multiplo HBc/HIV/HCV test, where it will be used by
customers in military, public health, tissue banking, and
mainstream healthcare sectors.
About MedMira
MedMira is a leading developer and manufacturer of
vertical flow rapid diagnostics. The Company's tests provide
hospitals, labs, clinics and individuals with instant diagnosis for
diseases such as HIV and hepatitis C in just three easy steps. The
Company's tests are sold under the
Revealâ, Multiplo and
Miriad™ brands in global markets. Based on its patented Rapid
Vertical Flow Technology™, MedMira's rapid HIV test is the only one
in the world to achieve regulatory approvals in Canada, the United
States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova
Scotia, Canada. For more information visit
medmira.com.
This news release contains forward-looking statements,
which involve risk and uncertainties and reflect the Company's
current expectation regarding future events including statements
regarding possible approval and launch of new products, future
growth, and new business opportunities. Actual
events could materially differ from those projected herein and
depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of
clinical studies, uncertainties related to the regulatory approval
process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly
filings.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE MedMira Inc.